Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells

Immunology Letters

Volumn 109, Issue 2, 2007, Pages 145-154

  Malfitano, Anna Maria ^a   Toruner, Gokce Altay ^b   Gazzerro, Patrizia ^a   Laezza, Chiara ^b,c   Husain, Seema ^b   Eletto, Davide ^a   Orlando, Pierangelo ^c   De Petrocellis, Luciano ^d   Terskiy, Alexandra ^b   Schwalb, Marvin ^b   Vitale, Emilia ^b,d   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c CNR   (Italy)

^d CNR   (Italy)

Author keywords

Anadamide; Arvanil; CD36; Human peripheral blood mononuclear cells (PBMCs); RNA microarray

Indexed keywords

ANANDAMIDE; ARVANIL; CD28 ANTIGEN; CD3 ANTIGEN; CD36 ANTIGEN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; UPREGULATION;

ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD36; ARACHIDONIC ACIDS; CAPSAICIN; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYUNSATURATED ALKAMIDES; UP-REGULATION;

EID: 33947355412     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.02.004     Document Type: Article

References (69)

1. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
2. Di Marzo V., and Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostagland Leukotr Essent Fatty Acids 53 (1995) 1-11
3. Lee M., Yang K.H., and Kaminski N.E. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 275 (1995) 529-536
4. Mechoulam R., Ben Shabat S., Hanus L., Fride E., Vogel Z., Bayewitch M., et al. Endogenous cannabinoid ligands-chemical and biological studies. J Lipid Mediat Cell Signal 14 (1996) 45-49
5. De Petrocellis L., Melck D., Bisogno T., and Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 108 (2000) 191-209
6. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostagland Leukotr Essent Fatty Acids 66 (2002) 377-391
7. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacology 54 (2002) 161-202 [review]
8. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., and Porrino L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 (2004) 345-358
9. Egertova M., Cravatt B.F., and Elphick B.F. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signalling. Neuroscience 119 (2003) 481-496
10. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romanini C., and Finazzi-Agrò A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J Immunol 166 (2001) 7183-7189
11. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol 74 (2003) 486-496
12. Do Y., McKallip R.J., Nagarkatti M., and Nagarkatti P.S. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173 (2004) 2373-2382
13. Nunez E., Benito C., Pazos M.R., Barbachano A., Fajardo O., Gonzalez S., et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53 (2004) 208
14. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
15. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
16. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457
17. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129 (2000) 227-230
18. Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., et al. Unsaturated long-chain N-acyl-vanillil-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptor. Biochem Biophys Res Commun 262 (1999) 275-284
19. Cabral G.A., Toney D.M., Fischer-Stenger K., Harrison M.P., and Marciano-Cabral F. Anandamide inhibits macrophage-mediated killing of tumour necrosis factor-sensitive cells. Life Sci 56 23/24 (1995) 2065-2072
20. Cabral G.A., and Staab A. Effects on the immune system. Handb Exp Pharmacol 168 (2005) 385-423
21. Malfitano A.M., Matarese G., and Bifulco M. From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases. Curr Drug Targets CNS Neurol Disord 4 6 (2005) 667-675
22. Parolaro D., Massi P., Rubino T., and Monti E. Endocannabinoids in the immune system and cancer. Prostagland Leukotr Essent Fatty Acids 66 (2002) 319
23. Klein T.W., Newton C., and Friedman H. Cannabinoid receptors and immunity. Immunol Today 19 8 (1998) 373-381
24. Berdyshev E., Boichot E., Germain N., Allain N., Anger J.P., and Lagente V. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330 (1997) 231-240
25. Molina-Holgado F., Molina-Holgado E., and Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 433 (1998) 139-142
26. Richardson J.D., Aanonsen L., and Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345 (1998) 145-153
27. Malfitano A.M., Matarese G., Pisanti S., Grimaldi C., Laezza C., Bisogno T., et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J Neuroimmunol 171 1/2 (2005) 110-119
28. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000) 84-87
29. Brooks J.W., Pryce G., Bisogno T., Jaggar S.I., Hankey D.J., Brown P., et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic site of action different from the vanilloid VR1 and cannabinoid receptor CB(1) CB(2) receptors. Eur J Pharmacol 439 1-3 (2002) 83-92
30. Savill J., Hogg N., Ren Y., and Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90 (1992) 1513-1522
31. Zhu H., Cong J.P., Mamtora G., Gingeras T., and Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci USA 95 (1998) 14470-14475
32. Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262 (1999) 275-284
33. Schwarz H., Blanco F.J., and Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 55 1 (1994) 107-115
34. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., and White Protter R.T.A.A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268 (1993) 11811-11816
35. Febbraio M., Hajjar D.P., and Silverstein R.L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108 6 (2001) 785-791
36. Walz D.A. Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer Metastasis Rev 11 3/4 (1992) 313-324
37. Huh H.Y., Pearce S.F., Yesner L.M., Schindler J.L., and Silverstein R.L. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 87 (1996) 2020-2028
38. Konig H., Pfisterer P., Corcoran L.M., and Wirth T. Identification of CD36 as the first gene dependent on the B-cell differentiation factor Oct-2. Genes Dev 9 (1995) 1598-1607
39. Swerlick R.A., Lee K.H., Wick T.M., and Lawley T.J. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 148 (1992) 78-83
40. Ockenhouse C.F., Tandon N.N., Magowan C., Jamieson G.A., and Chulay J.D. Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science 243 (1989) 1469-1471
41. Nakahata T., and Okumura N. Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leuk Lymphoma 13 (1994) 401-409
42. Acton S.L., Scherer P.E., Lodish H.F., and Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 269 (1994) 21003-21009
43. Lisanti M.P., Scherer P.E., Vidugiriene J., Tang Z., Hermanowski-Vosatka A., Tu Y.H., et al. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 126 (1994) 111-126
44. Lee H., Woodman S.E., Engelman J.A., Volonte D., Galbiati F., Kaufman H.L., et al. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase. J Biol Chem 276 37 (2001) 35150-35158
45. Savill J., Hogg N., and Haslett C. Macrophage vitronectin receptor, CD36, and thrombospondin cooperate in recognition of neutrophils undergoing programmed cell death. Chest 99 (1991) 6S-7S
46. Bird D.A., Gillotte K.L., Horkko S., Friedman P., Dennis E.A., Witztum J.L., et al. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. Proc Natl Acad Sci USA 96 (1999) 6347-6352
47. Chang M.K., Bergmark C., Laurila A., Horkko S., Han K.H., Friedman P., et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 96 (1999) 6353-6358
48. Abumrad N.A., el-Maghrabi M.R., Amri E.Z., Lopez E., and Grimaldi P.A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 268 (1993) 17665-17668
49. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138 (1997) 707-717
50. Xu Z., Ford G.D., Croslan D.R., Jiang J., Gates A., Allen R., et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis 19 3 (2005) 461-470
51. Xu Z., Jiang J., Ford G., and Ford B.D. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun 322 2 (2004) 440-446
52. Schwarz E.C., Wolfs M.J., Tonner S., Wenning A.S., Quintana A., Griesemer D., et al. TRP channels in lymphocytes. Handb Exp Pharmacol 179 (2007) 445-456
53. Saunders C.I., Kunde D.A., Crawford A., and Geraghty D.P. Expression of transient receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral blood. Mol Immunol 44 6 (2007) 1429-1435
54. Sancho R., de la Vega L., Appendino G., Di Marzo V., Macho A., and Munoz E. The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway. Br J Pharmacol 140 6 (2003) 1035-1044
55. Bilican B., and Goding C.R. Cell cycle regulation of the T-box transcription factor Tbx2. Exp Cell Res 312 12 (2006) 2358-2366
56. Monte M., Collavin L., Lazarevic D., Utrera R., Dragani T.A., and Schneider C. Cloning, chromosome mapping and functional characterization of a human homologue of murine gtse-1 (B99) gene. Gene 254 1/2 (2000) 229-236
57. Monte M., Benetti R., Collavin L., Marchionni L., Del Sal G., and Schneider C. hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem 279 12 (2004) 11744-11752
58. Hu L.Y., Tepper C.G., Lo S.H., and Lin W.C. An efficient strategy to identify early TPA-responsive genes during differentiation of HL-60 cells. Gene Expr 13 3 (2006) 179-189
59. Zhu Q., Pearson-White S., and Luo K. Requirement for the SnoN oncoprotein in transforming growth factor beta-induced oncogenic transformation of fibroblast cells. Mol Cell Biol 25 24 (2005) 10731-10744
60. Pearson-White S., and McDuffie M. Defective T-cell activation is associated with augmented transforming growth factor Beta sensitivity in mice with mutations in the Sno gene. Mol Cell Biol 23 15 (2003) 5446-5459
61. Nakagawa T., Nozaki S., Nishida M., Yakub J.M., Tomiyama Y., Nakata A., et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1350-1357
62. Liu L., Moesner P., Kovach N.L., Baily R., Hamilton A.D., Sebti S.M., et al. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem 274 (1999) 33334-33340
63. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 1 (2001) 48-52
64. Ruiz-Velasco N., Dominguez A., and Vega M.A. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands. Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem Pharmacol 67 2 (2004) 303-313
65. Munteanu A., Taddei M., Tamburini I., Bergamini E., Azzi A., and Zingg J.M. Antagonistic effects of oxidized low density lipoprotein and alpha-tocopherol on CD36 scavenger receptor expression in monocytes: involvement of protein kinase B and peroxisome proliferator-activated receptor-gamma. J Biol Chem 281 10 (2006) 6489-6497
66. Baruch D.I., Gormley J.A., Ma C., Howard R.J., and Pasloske B.L. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 93 (1996) 3497-3502
67. Borst P., Bitter W., McCulloch R., van Leeuwan F., and Rudenko G. Antigenic variation in malaria. Cell 82 (1995) 1-4
68. Turner G.D.H., Morrison H., Jones M., Davis T.M.E., Looareesuwan S., Buley I.D., et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 145 (1994) 1057-1069
69. Dobbie M.S., Hurst R.D., Klein N.J., and Surtees R.A.H. Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-alpha in an in vitro model of the blood-brain barrier. Brain Res 830 (1999) 330-336